Technical Analysis for ORPN - Bio Blast Pharma Ltd.

Grade Last Price % Change Price Change
grade C 10.82 0.93% 0.10
ORPN closed up 0.93 percent on Monday, March 18, 2019, on 37 percent of normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Flat Up Down
See historical ORPN trend table...

Date Alert Name Type % Chg
Mar 18 Crossed Above 200 DMA Bullish 0.00%
Mar 18 Doji - Bullish? Reversal 0.00%
Mar 18 Multiple of Ten Bullish Other 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 15 Fell Below 200 DMA Bearish 0.93%
Mar 15 Fell Below 20 DMA Bearish 0.93%
Mar 15 Calm After Storm Range Contraction 0.93%
Mar 15 Narrow Range Bar Range Contraction 0.93%
Mar 15 NR7 Range Contraction 0.93%
Mar 15 NR7-2 Range Contraction 0.93%

Older signals for ORPN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Bio Blast Pharma Ltd., a clinical-stage biotechnology company, develops therapies for patients with rare and ultra-rare genetic diseases. Its products include Cabaletta, a mutant protein stabilizing platform based on a small repurposed molecule to treat oculopharyngeal muscular dystrophy, Machado Joseph disease or SCA3, and Kennedy's disease or SBMA; and BBrm, a read-through platform based on a small repurposed molecule that enables the read-through (or bypassing) of genetic defects called nonsense mutations or stop codons that interfere with normal protein formation to treat diseases caused by nonsense mutation. The company's products also comprise mPRT, a mitochondrial protein replacement platform based on biological fusion proteins to treat mitochondrial protein deficiency diseases (Friedrich's Ataxia and ornithine transcarbamylase deficiency) by replacing missing or mutated proteins into mitochondria, and restoring cell function. Bio Blast Pharma Ltd. was founded in 2012 and is headquartered in Tel Aviv, Israel.
Biotechnology Biology Diseases Rare Diseases Gene Expression Molecular Genetics Oculopharyngeal Muscular Dystrophy Genetic Code Protein Biosynthesis Mitochondrion Nonsense Mutation
Is ORPN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 30.0
52 Week Low 6.16
Average Volume 32,529
200-Day Moving Average 10.8147
50-Day Moving Average 9.661
20-Day Moving Average 11.2685
10-Day Moving Average 11.609
Average True Range 1.6036
ADX 42.32
+DI 23.7254
-DI 19.3604
Chandelier Exit (Long, 3 ATRs ) 12.5492
Chandelier Exit (Short, 3 ATRs ) 13.610800000000001
Upper Bollinger Band 13.5481
Lower Bollinger Band 8.9889
Percent B (%b) 0.4
BandWidth 40.459689
MACD Line 0.4263
MACD Signal Line 0.5904
MACD Histogram -0.1641
Fundamentals Value
Market Cap 36.17 Million
Num Shares 3.34 Million
EPS -3.67
Price-to-Earnings (P/E) Ratio -2.95
Price-to-Sales 0.00
Price-to-Book 1.82
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.76
Resistance 3 (R3) 12.62 11.85 12.43
Resistance 2 (R2) 11.85 11.35 11.91 12.33
Resistance 1 (R1) 11.33 11.05 11.59 11.47 12.22
Pivot Point 10.56 10.56 10.68 10.62 10.56
Support 1 (S1) 10.04 10.06 10.30 10.17 9.42
Support 2 (S2) 9.27 9.76 9.33 9.31
Support 3 (S3) 8.75 9.27 9.21
Support 4 (S4) 8.88